Xenon Pharmaceuticals (XENE) Net Cash Flow (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Net Cash Flow data on file, last reported at $346.8 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 1434.44% year-over-year to $346.8 million in Q1 2026; TTM through Mar 2026 was $428.8 million, a 625.21% increase from a year earlier, with the FY2025 full-year figure at $56.0 million, up 1414.7% from the prior year.
• Net Cash Flow for Q1 2026 stood at $346.8 million, up from $94.8 million in the prior quarter.
• Over the last five years, Net Cash Flow for XENE reached as high as $346.8 million in Q1 2026 and fell as low as -$263.8 million in Q3 2022.
• Historically, Net Cash Flow has averaged $20.2 million across 5 years, with a median of $5.8 million in 2023.
• On a YoY basis, Net Cash Flow climbed as much as 5427.59% in 2022 and fell as far as 5053.06% in 2022.
• Year by year, Net Cash Flow stood at -$47.1 million in 2022, then soared by 203.74% to $48.8 million in 2023, then grew by 15.21% to $56.2 million in 2024, then jumped by 68.46% to $94.8 million in 2025, then surged by 266.04% to $346.8 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $346.8 million in Q1 2026, $94.8 million in Q4 2025, and -$30.9 million in Q3 2025.